Caffeine, postmenopausal estrogen, and risk of Parkinson's disease

被引:177
作者
Ascherio, A
Chen, H
Schwarzschild, MA
Zhang, SM
Colditz, GA
Speizer, FE
机构
[1] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA
[2] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA
[3] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA
[4] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA
[5] Harvard Univ, Sch Med, Div Prevent Med, Boston, MA 02115 USA
[6] Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA 02115 USA
[7] Harvard Univ, Sch Med, Channing Lab, Boston, MA 02115 USA
[8] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA
关键词
D O I
10.1212/01.WNL.0000046523.05125.87
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Men who regularly consume caffeinated drinks have a lower risk of PD than do nondrinkers, but this relation has not been found in women. Because this sex difference could be due to hormonal effects, the authors examined prospectively the risk of PD according to use of postmenopausal hormones and caffeine intake among participants in the Nurses' Health Study. Methods: The study population comprised 77,713 women free of PD, stroke, or cancer at baseline, who were postmenopausal at baseline or reached menopause before the end of the study. During 18 years of follow-up the authors documented 154 cases of PD. Results: Overall, the risk of PD was similar in women using hormones and women who never used hormones (relative risk 1.02, 95% CI 0.69 to 1.52). Use of hormones, however, was associated with a reduced risk of PD among women with low caffeine consumption (RR 0.39, 95% CI 0.13 to 1.17), and with increased risk among women with high caffeine consumption (RR 2.44, 95% CI 0.75 to 7.86; p for interaction = 0.01). Among hormone users, women consuming six or more cups of coffee per day had a fourfold higher risk of PD (RR 3.92, 95% CI 1.49 to 10.34; p = 0.006) than did women who never drink coffee. Conclusions: These results suggest that caffeine reduces the risk of PD among women who do not use postmenopausal hormones, but increases risk among hormone users. Clinical trials of caffeine or estrogens in women should avoid the combined use of these agents.
引用
收藏
页码:790 / 795
页数:6
相关论文
共 60 条
[1]   IMPAIRMENT OF CAFFEINE CLEARANCE BY CHRONIC USE OF LOW-DOSE ESTROGEN-CONTAINING ORAL-CONTRACEPTIVES [J].
ABERNETHY, DR ;
TODD, EL .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1985, 28 (04) :425-428
[2]  
Arnaud MJ, 1993, CAFFEINE COFFEE HLTH, P43
[3]   Prospective study of caffeine consumption and risk of Parkinson's disease in men and women [J].
Ascherio, A ;
Zhang, SMM ;
Hernán, MA ;
Kawachi, I ;
Colditz, GA ;
Speizer, FE ;
Willett, WC .
ANNALS OF NEUROLOGY, 2001, 50 (01) :56-63
[4]   Parkinson's disease and parkinsonism in a longitudinal study - Two-fold higher incidence in men [J].
Baldereschi, M ;
Di Carlo, A ;
Rocca, WA ;
Vanni, P ;
Maggi, S ;
Perissinotto, E ;
Grigoletto, F ;
Amaducci, L ;
Inzitari, D .
NEUROLOGY, 2000, 55 (09) :1358-1363
[5]  
BEDARD P, 1977, LANCET, V2, P1367
[6]   Hysterectomy, menopause, and estrogen use preceding Parkinson's disease: An exploratory case-control study [J].
Benedetti, MD ;
Maraganore, DM ;
Bower, JH ;
McDonnell, SK ;
Peterson, BJ ;
Ahlskog, JE ;
Schaid, DJ ;
Rocca, WA .
MOVEMENT DISORDERS, 2001, 16 (05) :830-837
[7]   Smoking, alcohol, and coffee consumption preceding Parkinson's disease - A case-control study [J].
Benedetti, MD ;
Bower, JH ;
Maraganore, DM ;
McDonnell, SK ;
Peterson, BJ ;
Ahlskog, JE ;
Schaid, DJ ;
Rocca, WA .
NEUROLOGY, 2000, 55 (09) :1350-1358
[8]   Short-term effects of high-dose 17β-estradiol in postmenopausal PD patients -: A crossover study [J].
Blanchet, PJ ;
Fang, J ;
Hyland, K ;
Arnold, LA ;
Mouradian, MM ;
Chase, TN .
NEUROLOGY, 1999, 53 (01) :91-95
[9]   Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990 [J].
Bower, JH ;
Maraganore, DM ;
McDonnell, SK ;
Rocca, WA .
NEUROLOGY, 1999, 52 (06) :1214-1220
[10]   CHANGES IN RATE AND PATTERN OF CAFFEINE METABOLISM AFTER CIGARETTE ABSTINENCE [J].
BROWN, CR ;
JACOB, P ;
WILSON, M ;
BENOWITZ, NL .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1988, 43 (05) :488-491